Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse physiological
functions. Its two isoforms (α and β) are widely expressed throughout the body in sensory …

Migraine is a debilitating disease whose clinical and social impact is out of debate.
Tolerability issues, interactions, contraindications, and inefficacy of the available …

The development of small-molecule calcitonin gene-related peptide (CGRP) receptor
antagonists (gepants) and of monoclonal antibodies targeting the CGRP system has been a …

After 35 years since the introduction of the International Classification of Headache
Disorders (ICHD), we are living in the era of the second great revolution in migraine …

Abstract Purpose of Review To summarize available calcitonin gene-related peptide
(CGRP)-targeting therapies for migraine and discuss their use in real-world populations …

Migraine is a common and disabling neurological disorder, with several manifestations, of
which pain is just one. Despite its worldwide prevalence, there remains a paucity of targeted …

Background Long-term data helps assess the consistency of efficacy, tolerability, and safety
of acute treatment over repeated use for different attacks. Real-world studies help assess …

Objective To evaluate potential drug–drug interactions of ubrogepant and atogepant.
Background Ubrogepant and atogepant, calcitonin gene‐related peptide (CGRP) receptor …

Since the discovery of calcitonin gene‐related peptide (CGRP) in 1982, its integral role in
migraine pathophysiology, specifically migraine pain, has been demonstrated through …

Introduction Although acute and preventive treatments for migraine are commonly given in
combination, data on the real-world effectiveness of ubrogepant as an acute treatment when …